Ropes Wealth Advisors’s Eledon Pharmaceuticals ELDN Stock Holding History

Ropes Wealth Advisors’s Portfolio ELDN Stock Details ELDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-37	Closed	-$9K	–	492
2016 Q3	$9K	Hold	37	–	–	﹤0.01%	415
2016 Q2	$33K	Hold	37	–	–	0.01%	299
2016 Q1	$34K	Hold	37	–	–	0.02%	245
2015 Q4	$52K	Hold	37	–	–	0.02%	242
2015 Q3	$62K	Hold	37	–	–	0.03%	231
2015 Q2	$80K	Buy	+37	New	+$71.6K	0.04%	167

Other funds holding ELDN

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ropes Wealth Advisors's ELDN Position: Q4 2016 in Review

Ropes Wealth Advisors sold out of Eledon Pharmaceuticals (ELDN) in Q4 2016, closing a stake of 37 shares — an estimated $9K sold.

Ropes Wealth Advisors first reported a position in ELDN in Q2 2015 and held it in 6 quarters. The position peaked at $80K in Q2 2015. 42 funds tracked by Wall St. Rank hold ELDN as of Q4 2016.

Ropes Wealth Advisors reported no remaining Eledon Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Ropes Wealth Advisors sold 37 Eledon Pharmaceuticals shares in Q4 2016, an estimated $9K.
Ropes Wealth Advisors first reported a position in Eledon Pharmaceuticals in Q2 2015 and held it in 6 quarters.
Ropes Wealth Advisors's Eledon Pharmaceuticals position peaked at $80K in Q2 2015.
42 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q4 2016.

Based on Ropes Wealth Advisors's 13F filing for Q4 2016, filed 6 Jan 2017.